Fong LCW, Lee NHC, Yan AT, et al. - In the treatment of acute coronary syndrome cases, ticagrelor compared with prasugrel did not decrease the primary composite endpoint of myocardial infarction (MI), stroke and cardiovascular death at a weighted mean follow up of 11 months.

• A meta-analysis of 11 eligible RCTs with 6,098 acute coronary syndrome patients randomized to prasugrel (n=3,050) or ticagrelor (n=3,048).

• In the prasugrel and the ticagrelor arms, the composite endpoint events [MI, stroke or cardiovascular death] occurred in 180 and 207 patients, respectively, during a weighted mean follow up of 11±2 months.

• Similar risk in the primary composite endpoint was noted in the ticagrelor group vs prasugrel (Risk Ratio RR = 1.17).

• In terms of stroke (RR=1.05); cardiovascular death (RR=1.01); Bleeding Academic Research Consortium type 2 or above bleeding (RR=1.16); stent thrombosis (RR=1.58); all cause death (RR=1.10) except MI (RR=1.38), there was no significant difference between ticagrelor vs prasugrel.